Drug Profile
ARGX 116
Alternative Names: ARGX-116; STT 5058Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator argenx
- Developer Staten Biotechnology
- Class Antibodies; Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action Apolipoprotein C-III inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias; Hypertriglyceridaemia
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Hypertriglyceridaemia in United Kingdom (IV)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Hypertriglyceridaemia in United Kingdom (SC)
- 31 Dec 2022 Staten Biotechnology terminates its collaboration with Novo Nordisk for the development of ARGX 116, prior to February 2023